{
    "nctId": "NCT03970967",
    "briefTitle": "Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases",
    "officialTitle": "A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Carcinoma, Metastatic Breast Cancer, Invasive Breast Cancer, Distant Metastases.Pathology",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "Tumor response to DaRT",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with histopathological confirmation of primary (or recurrent) invasive breast carcinoma and distant metastatic disease at diagnosis.\n* Target tumor size \u2264 3.0 cm (T1-2b category);\n* Morphological type: invasive breast cancer\n* Luminal-type A (ER+, PR+, Her2/neu +1), HER+, luminal-type B (ER +/-, PR +/-, Her2/neu+1), or Triple negative breast carcinoma\n* Measurable disease according to RECIST v1.1.\n* Subjects over 45 years old.\n* Subjects' ECOG Performance Status Scale is \\< 2.\n* Subjects' life expectancy more than 6 months.\n* Platelet count \u2265100,000/mm3.\n* International normalized ratio of prothrombin time \u22641.8.\n* Creatinine \u22641.9 mg/dL.\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.\n* Subjects are willing to sign an informed consent form.\n\nExclusion Criteria:\n\n* T4 category with skin involvement.\n* Regional lymph node metastases.\n* Ductal carcinoma in situ.\n* Inflammatory breast carcinoma.\n* Patients with pre-irradiation of the breast.\n* Acute infection disease.\n* The presence of HIV, RW, HbsAg, HCV in the acute stage.\n* Pregnancy or lactation.\n* Serious competing (somatic) diseases incompatible according to the researcher with brachytherapy.\n* Mental illness.\n* Patients undergoing immunosuppressive and/or systemic corticosteroid treatment\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)\n* Subjects not willing to sign an informed consent.",
    "sex": "ALL",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}